Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013-2017

被引：14

作者：

Shimbashi, Reiko ^{[1
,2
]}

Suzuki, Motoi ^{[1
,2
]}

Chang, Bin ^{[1
]}

Watanabe, Hiroshi ^{[3
]}

Tanabe, Yoshinari ^{[4
]}

Kuronuma, Koji ^{[5
]}

Oshima, Kengo ^{[2
]}

Maruyama, Takaya ^{[6
]}

Takeda, Hiroaki ^{[7
]}

Kasahara, Kei ^{[8
]}

Fujita, Jiro ^{[9
]}

Nishi, Junichiro ^{[10
]}

Kubota, Tetsuya ^{[11
]}

Tanaka-Taya, Keiko ^{[1
]}

Matsui, Tamano ^{[1
]}

Sunagawa, Tomimasa ^{[1
]}

Oishi, Kazunori ^{[1
,12
]}

机构：

[1] Natl Inst Infect Dis, Tokyo, Japan

[2] Tohoku Univ, Grad Sch Med, Sendai, Miyagi, Japan

[3] Kurume Univ, Sch Med, Fukuoka, Japan

[4] Niigata Prefectural Shibata Hosp, Niigata, Japan

[5] Sapporo Med Univ, Sch Med, Sapporo, Hokkaido, Japan

[6] Natl Hosp Org Mie Natl Hosp, Tsu, Mie, Japan

[7] Yamagata Saisei Hosp, Yamagata, Japan

[8] Nara Med Univ, Nara, Japan

[9] Univ Ryukyus, Grad Sch Med, Nishihara, Okinawa, Japan

[10] Kagoshima Univ, Grad Sch Med & Dent Sci, Kagoshima, Japan

[11] Kochi Univ, Kochi Med Sch, Kochi, Japan

[12] Toyama Inst Hlth, Toyama, Japan

来源：

EMERGING INFECTIOUS DISEASES | 2020年 / 26卷 / 10期

关键词：

PNEUMONIAE SEROTYPE 12F; CONJUGATE VACCINE; POPULATION; IMPACT; OLDER; SPAIN;

D O I：

10.3201/eid2610.191531

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The decline in the proportion of pneumococcal conjugate vaccine (PCV)-covered serotypes among adult invasive pneumococcal disease (IPD) patients might change the overall effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) because its effectiveness differs according to serotype. Using the indirect cohort method, we calculated the effectiveness of PPSV23 against IPD among adults in Japan to assess the impact of the national pediatric PCV program. Clinical and epidemiologic information and pneumococcal isolates were collected from IPD patients >= 20 years of age through enhanced IPD surveillance during April 2013-December 2017. Adjusted effectiveness against PPSV23-serotype IPD was 42.2%. Despite a substantial decline in the proportion of 13-valent PCV serotypes during the study period (45% to 31%), the change in effectiveness for PPSV23-serotype IPD was limited (47.1% to 39.3%) and only marginal in the elderly population (39.9% to 39.4%). The pediatric PCV program had limited impact on PPSV23 effectiveness against IPD in adults.

引用

页码：2378 / 2386

页数：9

共 50 条

[21] Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against Invasive Disease and Hospital-Treated Pneumonia Among People Aged ≥65 Years: A Retrospective Case-Control Study
Leventer-Roberts, Maya
Feldman, Becca S.
Brufman, Ilan
Cohen-Stavi, Chandra J.
Hoshen, Moshe
Balicer, Ran D.
CLINICAL INFECTIOUS DISEASES, 2015, 60 (10) : 1472 - 1480
[22] Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in older adults
Hsiao, Amber
Lewis, Ned
Hansen, John
Timbol, Julius
Suaya, Jose A.
Alexander-Parrish, Ronika
Grant, Lindsay R.
Gessner, Bradford D.
Klein, Nicola P.
VACCINE, 2025, 44
[23] Cardiovascular, Neurological, and Immunological Adverse Events and the 23-Valent Pneumococcal Polysaccharide Vaccine
Yoon, Dongwon
Jeon, Ha-Lim
Kim, Ju Hwan
Lee, Hyesung
Shin, Ju-Young
JAMA NETWORK OPEN, 2024, 7 (01)
[24] Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
Peterson, James T.
Stacey, Helen L.
MacNair, John E.
Li, Jianing
Hartzel, Jonathan S.
Sterling, Tina M.
Benner, Patrice
Tamms, Gretchen M.
Musey, Luwy K.
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (03) : 540 - 548
[25] Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine
Bryant, K. A.
Frenck, R.
Gurtman, A.
Rubino, J.
Treanor, J.
Thompson, A.
Jones, T. R.
Sundaraiyer, V.
Baxter, L. M.
Gruber, W. C.
Emini, E. A.
Scott, D. A.
Schmoele-Thoma, B.
VACCINE, 2015, 33 (43) : 5854 - 5860
[26] Incremental effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia hospitalisation among Australian Indigenous children: A record linkage study
Kabir, Alamgir
Randall, Deborah
Newall, Anthony T.
Moore, Hannah C.
Jayasinghe, Sanjay
Fathima, Parveen
Liu, Bette
Mcintyre, Peter
Gidding, Heather F.
VACCINE, 2023, 41 (37) : 5454 - 5460
[27] Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the Region of Madrid, Spain, 2008-2011
Gutierrez Rodriguez, M. A.
Ordobas Gavin, M. A.
Garcia-Comas, L.
Sanz Moreno, J. C.
Cordoba Deorador, E.
Lasheras Carbajo, M. D.
Taveira Jimenez, J. A.
Martin Martinez, F.
Iniesta Fornies, D.
Arce Arnaez, A.
EUROSURVEILLANCE, 2014, 19 (40) : 35 - 43
[28] A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan
Jiang, Yiling
Yang, Xiaoqin
Taniguchi, Kazuko
Petigara, Tanaz
Abe, Machiko
JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (07) : 687 - 697
[29] Cost-Effectiveness Analysis of Universal Vaccination of Adults Aged 60 Years with 23-Valent Pneumococcal Polysaccharide Vaccine versus Current Practice in Brazil
de Soarez, Patricia Coelho
Christovam Sartori, Ana Marli
Freitas, Angela Carvalho
Nishikawa, Alvaro Mitsunori
Dutilh Novaes, Hillegonda Maria
PLOS ONE, 2015, 10 (06):
[30] Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan
Hoshi, Shu-ling
Kondo, Masahide
Okubo, Ichiro
PLOS ONE, 2015, 10 (10):

← 1 2 3 4 5 →